# T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Source: https://onco.cc/trials/nct06045767/  
OnCo record `nct06045767` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Ari Raphael, not yet recruiting.

## Summary

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer is a phase 2, interventional study registered as NCT06045767 by Ari Raphael, with a registry enrolment figure of 30 participants, started 2024-06 and due to reach its primary completion in 2029-01. Interventions recorded: Pembrolizumab 50 MG Injection [Keytruda]. Conditions listed: Non-small Cell Lung Cancer Metastatic. Primary outcome: Objective Response Rate (ORR) per RECIST 1.1 - correlated to TCR repertoire data, such as clonality/diversity.. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06045767
- Phase: 2
- Setting: T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
- Sponsor: Ari Raphael
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06045767: https://clinicaltrials.gov/study/NCT06045767

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06045767.json